Agios Pharmaceuticals Financial Statements (AGIO)
|
|
|
|
Report date
|
|
|
24.02.2022 |
23.02.2023 |
15.02.2024 |
13.02.2025 |
12.02.2026 |
|
29.04.2026 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
0.000 |
14.2 |
26.8 |
36.5 |
54.0 |
|
66.0 |
|
Operating Income, bln rub |
|
|
-378.4 |
-389.0 |
-391.5 |
-425.7 |
-472.1 |
|
-475.5 |
|
EBITDA, bln rub |
? |
|
-337.7 |
-380.5 |
-384.9 |
-420.1 |
-467.0 |
|
-470.3 |
|
Net profit, bln rub |
? |
|
1 605 |
-231.8 |
-352.1 |
673.7 |
-412.8 |
|
-422.6 |
|
|
OCF, bln rub |
? |
|
-407.3 |
-309.5 |
-296.1 |
-389.8 |
-373.0 |
|
-380.4 |
|
CAPEX, bln rub |
? |
|
5.74 |
4.88 |
0.999 |
1.69 |
4.32 |
|
4.32 |
|
FCF, bln rub |
? |
|
-413.1 |
-314.4 |
-297.1 |
-391.5 |
-377.3 |
|
-384.7 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
359.6 |
401.6 |
408.8 |
458.1 |
514.6 |
|
529.7 |
|
Cost of production, bln rub |
|
|
18.8 |
1.70 |
9.50 |
4.17 |
11.5 |
|
11.8 |
|
R&D, bln rub |
|
|
257.0 |
279.9 |
288.9 |
301.3 |
334.4 |
|
342.7 |
|
Interest expenses, bln rub |
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Assets, bln rub |
|
|
1 438 |
1 239 |
937.1 |
1 663 |
1 297 |
|
1 185 |
|
Net Assets, bln rub |
? |
|
1 292 |
1 101 |
811.0 |
1 541 |
1 193 |
|
1 109 |
|
Debt, bln rub |
|
|
97.1 |
85.7 |
72.0 |
57.0 |
62.0 |
|
35.7 |
|
Cash, bln rub |
|
|
1 020 |
783.1 |
776.9 |
893.7 |
854.4 |
|
737.0 |
|
Net debt, bln rub |
|
|
-922.9 |
-697.5 |
-704.9 |
-836.7 |
-792.4 |
|
-701.3 |
|
|
Ordinary share price, rub |
|
|
32.9 |
28.1 |
22.3 |
32.9 |
27.2 |
|
28.2 |
|
Number of ordinary shares, mln |
|
|
60.4 |
54.8 |
55.7 |
56.8 |
58.0 |
|
58.8 |
|
|
Market cap, bln rub |
|
|
1 987 |
1 538 |
1 239 |
1 867 |
1 578 |
|
1 656 |
|
EV, bln rub |
? |
|
1 064 |
841 |
534 |
1 030 |
786 |
|
955 |
|
Book value, bln rub |
|
|
1 292 |
1 101 |
811 |
1 541 |
1 193 |
|
1 109 |
|
|
EPS, rub |
? |
|
26.5 |
-4.23 |
-6.33 |
11.9 |
-7.12 |
|
-7.19 |
|
FCF/share, rub |
|
|
-6.83 |
-5.74 |
-5.34 |
-6.89 |
-6.51 |
|
-6.54 |
|
BV/share, rub |
|
|
21.4 |
20.1 |
14.6 |
27.1 |
20.6 |
|
18.9 |
|
|
EBITDA margin, % |
? |
|
|
-2 672% |
-1 435% |
-1 151% |
-864.3% |
|
-712.0% |
|
Net margin, % |
? |
|
|
-1 628% |
-1 313% |
1 846% |
-764.0% |
|
-639.8% |
|
FCF yield, % |
? |
|
-20.8% |
-20.4% |
-24.0% |
-21.0% |
-23.9% |
|
-23.2% |
|
ROE, % |
? |
|
124.2% |
-21.1% |
-43.4% |
43.7% |
-34.6% |
|
-38.1% |
|
ROA, % |
? |
|
111.6% |
-18.7% |
-37.6% |
40.5% |
-31.8% |
|
-35.7% |
|
|
P/E |
? |
|
1.24 |
-6.64 |
-3.52 |
2.77 |
-3.82 |
|
-3.92 |
|
P/FCF |
|
|
-4.81 |
-4.89 |
-4.17 |
-4.77 |
-4.18 |
|
-4.30 |
|
P/S |
? |
|
|
108.0 |
46.2 |
51.1 |
29.2 |
|
25.1 |
|
P/BV |
? |
|
1.54 |
1.40 |
1.53 |
1.21 |
1.32 |
|
1.49 |
|
EV/EBITDA |
? |
|
-3.15 |
-2.21 |
-1.39 |
-2.45 |
-1.68 |
|
-2.03 |
|
Debt/EBITDA |
|
|
2.73 |
1.83 |
1.83 |
1.99 |
1.70 |
|
1.49 |
|
|
R&D/CAPEX, % |
|
|
4 476% |
5 735% |
28 919% |
17 880% |
7 747% |
|
7 934% |
|
|
CAPEX/Revenue, % |
|
|
|
34.3% |
3.72% |
4.62% |
7.99% |
|
6.54% |
|
| Agios Pharmaceuticals shareholders |
